ChromaDex Corp (NAGE) - Long-Term Liabilities to Capital

The price action history of Chromadex Corp (NAGE) demonstrates a current level of 0.02. Chromadex Corp leads research into NAD+ and aging, holding exclusive patents for Niagen. The business relies on the demand for longevity supplements and the legal protection of its developments. Growth is driven by the expansion of wholesale supplies, although global promotion costs are limiting the growth of bottom-line profit.

This indicator measures the proportion of long-term liabilities relative to equity, determining the company's dependence on external debt financing for long-term planning. Analyzing the long-term debt-to-equity ratio allows for an assessment of the financial stability of Chromadex Corp. amid its expansion into the growing NAD+ and longevity products market, where the balance between leverage and autonomy impacts the pace of business scaling.